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Objective
To assay at what hemoglobin (Hb) levels patients
recieved transfusion support, and the impact that this
may have in prognosis and possible adverse effects in
patients admitted with aneurismatic subarachnoidal
hemorrage.
Methods
This is a retrospective observational study, including all
patients admitted in our hospital diagnosed of not-trau-
matic SAH, both in the Intensive Care Unit and in
Stroke Unit, between 2007 and 2014. Demographics,
cardiovascular risk factors, neurological deficit, GCS,
Hunt & Hess and Fisher scales, bleeding localization,
aneurysm, incidence of complications (hydrocephalus,
intracraneal hipertension, stroke, vasospasm), treatment
(surgical or endovascular) as well as mortality were col-
lected. We analyzed hemoglobin levels during the admit-
tance, dividing the patients in 3 categories: Hb < 7 g/dl,
Hb 7-9 g/dl and Hb > 9 g/dl. In each one of these groups
we collected data about transfusion, vasospasm, GOS at
1 month, and ranking at 3 months and one year.
Results
319 patients were included, 189 male (60%), 62% of
them smoked and 41% had high blood pressure (HBP).
Clinically, 24% of patients at admittance had neurologi-
cal deficit and 49% loss of consciousness, with GCS < 7
in 24% of them. 23’5% had level III in Fisher scale and
56% were Fisher IV. Arteriography was performed in
90% of the patients included. Endovascular treatment
was done in 52% versus 13% that needed surgical treat-
ment. As complications during admittance, patients
developed vasospasm in 35% of the cases (27% before
7 days) and stroke 23% of them. Intracranial hyperten-
sion was diagnosed in 38%, and global mortality the first
week was 12%. About 1’6% of patients included had
hemoglobin levels < 7 g/dl, and all of them recieved
transfusion support; 80% had stable levels of Hb above
9 g/dl and they were not transfused in any case. 18’2%
had levels between 7 and 9 g/dl, of whom 48% recieved
transfusion support. No statistically significant differ-
ences were observed when comparing patients trans-
fused with Hb between 7-9 g/dl, with the group who
did not recieved transfusion with same levels of Hb, in
terms of vasospasm incidence (41% vs 48%), GOS at
1 month and Rankin at 3 months and 1 year.
Conclusions
Patients diagnosed of aneurysmatic SAH with hemoglobin
levels between 7 and 9 g/dl, who are given transfusion
support with red blood cells, seem to have no benefit in
terms of complications and prognosis, when compared
with the ones not transfused.
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